Acquisition Announced

ANI Pharmaceuticals acquisition of Egetis

US$560m consideration

Announced 2026 (approx.)

Advisers

Egetis

Target

Financial adviser

ANI Pharmaceuticals

Acquirer

Not disclosed

Target
Egetis
Acquirer
ANI Pharmaceuticals
Target based in
Sweden
Buyer based in
United States
Sector
Pharma
Tags
Pharma, Rare Disease

In the league tables

Similar deals

All pharma deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.